Injectafer denied as duplicate or overlapping therapy by Blue Cross Blue Shield?

Blue Cross Blue Shield's specific coverage criteria for injectafer are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why BCBS Denies Injectafer as Duplicate Therapy — and Why That Denial Is Often Wrong

Injectafer (ferric carboxymaltose) is an intravenous iron replacement product. A duplicate-therapy denial from BlueCross BlueShield means the plan has determined that another drug already authorized or dispensed covers the same clinical purpose. This most commonly happens when an oral iron supplement or a different IV iron formulation (such as iron sucrose or low-molecular-weight iron dextran) is on file for the patient. However, IV iron formulations are not clinically interchangeable in all patients, and oral iron is not an equivalent alternative for patients who cannot absorb or tolerate it.

## Why This Denial Is Appealable

Duplicate-therapy logic works at the administrative level — it flags a drug class overlap without examining patient-specific clinical factors. The core of your appeal is that the alternative therapy on file is not, in fact, therapeutically equivalent for this patient. If your physician has documented that oral iron is contraindicated or has failed, or that the formulary IV iron alternative is not appropriate based on infusion volume, administration frequency, or clinical history, the duplicate-therapy determination does not withstand clinical scrutiny. Consult the FDA-approved prescribing information for Injectafer to identify the approved indications and patient populations, and compare them against the BCBS coverage policy to confirm that no appropriate equivalent is actually available to this patient.

## Federal Appeal Framework

• Internal appeal: File under ACA §2719 or ERISA §503. Request the specific duplicate-therapy basis — i.e., which drug BCBS considers duplicative — so your appeal can address it directly.
• External review: If denied internally, escalate to an Independent Review Organization within the approximately four-month window noted on your denial letter.
• Expedited review: Available if the patient's condition is acute or deteriorating; iron-deficiency anemia with symptomatic severity supports expedited processing.

## Concrete Appeal Steps and Timeline

1. Identify from the denial letter which specific drug BCBS flagged as duplicative. 2. Obtain documentation showing the patient's history with that flagged alternative — including failure, intolerance, contraindication, or clinical unsuitability. 3. Submit your internal appeal with prescriber letter within the deadline stated on the denial notice. 4. If internally denied, file for external review promptly.

## Documentation to Gather

• Diagnosis confirmation: Lab work and clinical notes confirming iron-deficiency anemia or the underlying condition requiring IV iron replacement.
• Prior therapy history: Dates, doses, and documented outcomes or adverse effects from oral iron or other IV iron alternatives.
• Clinical severity: Physician notes describing symptom burden, hemoglobin trajectory, and urgency of repletion.
• Prescriber medical-necessity letter: Explicit statement explaining why the flagged "duplicate" agent is not clinically equivalent for this patient and why Injectafer is specifically required.

## Criteria-Mapping Structure

Obtain BCBS's duplicate-therapy coverage policy for IV iron. For each criterion the plan uses to determine equivalence, provide a chart-based answer showing why the flagged alternative does not satisfy this patient's clinical situation. Pair each policy requirement with the corresponding note, lab result, or physician statement that distinguishes Injectafer from the plan's preferred alternative.